Switching from Mounjaro to Wegovy Tablet UK: Key Differences

# Switching from Mounjaro to Wegovy Tablet UK: Key Differences

Mounjaro (tirzepatide) has been the dominant weight loss injection in the UK private market since 2023. Hundreds of thousands of people are currently on it. With the Wegovy tablet approved by the MHRA in June 2026, some people on Mounjaro will naturally start wondering whether the oral option makes sense for them — particularly given the significant cost difference.

This is a reasonable question to ask. But switching from Mounjaro to the Wegovy tablet is a more substantial change than most people realise. This guide explains why, and what the switch would actually involve.

> **Medical disclaimer:** Wegovy tablets and Mounjaro are both prescription-only medicines. Any change in treatment must be assessed and guided by a qualified prescriber. **You must not self-switch between treatments.** The information in this guide is general and does not replace the advice of your clinician or the patient information leaflet supplied with your medication. Always speak to your prescriber before making any changes.

> **Switching compliance note:** Switching from Mounjaro to any other weight loss medication involves changing to a different drug entirely. There is no self-administered dose conversion. Any switch requires a clinical assessment by a prescriber who knows your history and goals.

—

## The fundamental difference: these are different drugs

This is the most important thing to understand before anything else. Mounjaro and the Wegovy tablet do not contain the same active ingredient.

**Mounjaro** contains tirzepatide — a dual agonist that activates both the GIP receptor and the GLP-1 receptor simultaneously. This dual mechanism is what distinguishes it from other weight loss treatments.

**Wegovy tablet** contains oral semaglutide — a GLP-1 receptor agonist only. Semaglutide (the same molecule used in the Wegovy injection and in Ozempic) activates the GLP-1 receptor but not the GIP receptor.

Switching from Mounjaro to the Wegovy tablet is not an equivalent swap within the same drug family. It is a change to a fundamentally different pharmacological agent. The mechanisms overlap — both activate GLP-1 receptors — but they are not the same.

—

## Why someone might consider switching

Despite the pharmacological difference, there are legitimate reasons people on Mounjaro might explore the Wegovy tablet:

**Cost.** Mounjaro from UK private providers typically costs £159–£268 per month depending on dose and provider. The Wegovy tablet starts from £64 per month. Over a 12-month treatment programme, the difference can exceed £1,000. For people paying out of pocket on a fixed budget, this is a significant factor.

**Needle-free format.** Mounjaro is injection-only — there is no oral version of tirzepatide currently approved in the UK. For people with significant needle anxiety who are managing that anxiety to remain on treatment, the existence of a tablet alternative is genuinely meaningful.

**Supply.** Mounjaro has experienced stock shortages in the UK since its launch. While supply has improved, some people have faced gaps in treatment. The Wegovy tablet is a new product with a separate supply chain and a growing number of providers.

—

## What the evidence says about comparative effectiveness

This is where the trade-off is most clear, and it is important to understand it honestly before switching.

**Mounjaro** (tirzepatide injection) has produced some of the highest weight loss results of any approved medication in clinical trials. SURMOUNT trial data showed average weight loss of approximately 20–22% at maximum dose.

**Wegovy injection** (semaglutide injection) showed approximately 20.7% average weight loss at maximum dose in STEP trial data.

**Wegovy tablet** (oral semaglutide) showed approximately 14–16% average weight loss at maximum dose in OASIS trial data.

The general picture: Mounjaro and the Wegovy injection produce broadly comparable weight loss, with Mounjaro having a modest but consistent evidence advantage. The Wegovy tablet produces meaningfully lower weight loss than either injection in clinical trial data.

Switching from Mounjaro to the Wegovy tablet therefore involves accepting a lower expected weight loss ceiling — typically several percentage points lower than what you might expect on Mounjaro at full dose.

That said, these are averages from clinical populations. Individual responses vary significantly. Some people do better on one molecule than another for reasons that are not fully predictable. Your prescriber can help you interpret what the evidence means for your specific situation.

—

## The switching process: what to expect

### A prescriber assessment is essential

Because you are changing to a different drug — not just a different formulation — your prescriber needs to assess whether the switch is appropriate for you, what starting dose to use, and how to manage the transition. You cannot self-switch.

You will almost certainly need to register with a new provider. Most Mounjaro providers do not currently stock the Wegovy tablet, and the two products come through different supply chains. A new clinical assessment will be required by the new provider even if your medical history is unchanged.

### Expect to start the Wegovy tablet dose escalation from the beginning

Your prescriber will almost certainly start you on the lowest Wegovy tablet dose (1.5mg daily) and escalate according to the standard schedule, regardless of how long you have been on Mounjaro or at what dose. This is because the two drugs work differently, the tablet has different absorption characteristics, and the dose escalation exists to manage gastrointestinal side effects — which are real even if you have tolerated Mounjaro well.

### There may be a gap between treatments

Your prescriber will advise on timing. Depending on their guidance, there may be a period between stopping Mounjaro and starting the Wegovy tablet. Mounjaro has a half-life that means it remains active in the body for some time after the last injection. Your prescriber will account for this.

### Side effects may differ

Mounjaro and oral semaglutide have similar side effect profiles — nausea, vomiting, diarrhoea, constipation — but they are different drugs and individual tolerance varies. Some people who have experienced significant GI side effects on Mounjaro find oral semaglutide more tolerable, or vice versa. This is not predictable in advance, and you should not assume your experience on one will mirror your experience on the other.

—

## Who might benefit from this switch despite the lower effectiveness ceiling?

Switching from Mounjaro to the Wegovy tablet makes most sense for people in one of these situations:

**People who have reached their weight loss goal.** If you achieved your target weight on Mounjaro and are moving into maintenance, a lower-cost oral option may be an appropriate alternative to continuing an expensive injection programme. Your prescriber will need to assess this.

**People with significant needle anxiety.** If every Mounjaro injection is a source of genuine stress and anxiety — not mild discomfort, but a significant barrier to consistent treatment — the existence of a needle-free alternative is clinically meaningful, even if it has a lower effectiveness ceiling.

**People for whom cost has become unsustainable.** Weight loss treatment is typically long-term. If the Mounjaro cost is becoming a barrier to continuing, a clinically reviewed switch to the Wegovy tablet may be preferable to stopping treatment entirely.

### Who should think carefully

– People who are still actively losing weight on Mounjaro and have not reached their goal — switching involves accepting a lower ceiling at a point when the higher-ceiling treatment is still working
– People who have responded very well to Mounjaro’s dual mechanism and are concerned about losing that specific pharmacological effect
– People who cannot commit to the daily fasting routine that the Wegovy tablet requires (30 minutes before eating or drinking anything except plain water)

—

## Frequently asked questions

### Is the Wegovy tablet as good as Mounjaro?

In clinical trial data, Mounjaro produces greater average weight loss than the Wegovy tablet. Mounjaro’s dual GIP/GLP-1 mechanism appears to offer an advantage over GLP-1-only oral semaglutide for most people. That said, the Wegovy tablet has real advantages: it is needle-free, significantly cheaper, and requires no refrigeration. Whether the trade-off is right for you is a decision to make with your prescriber.

### Will I lose the weight I’ve already lost if I switch?

Switching does not reverse weight already lost. However, restarting dose escalation on the Wegovy tablet — at a lower starting dose than your current Mounjaro dose — may mean appetite suppression is less strong during the transition period. Some weight regain during the switch is possible but not inevitable. Your prescriber can advise on how to manage this.

### Do I need to taper Mounjaro before starting the Wegovy tablet?

You should not make any changes to your Mounjaro treatment without advice from your prescriber. Whether to taper, stop abruptly, or observe a gap before starting the tablet depends on your clinical situation. This must be guided by a prescriber, not a general guide.

### Can the same clinic prescribe both Mounjaro and the Wegovy tablet?

Some providers may offer both, but many do not. You may need to find a new provider who stocks the Wegovy tablet. In either case, a clinical assessment will be required before a new prescription is issued.

### Will I regain weight if I switch from Mounjaro to the Wegovy tablet?

There is a risk of some weight regain during the transition, particularly while on the lower starting doses of the tablet. Once at an effective maintenance dose, weight loss may resume — though the overall ceiling is typically lower with the tablet than Mounjaro. Long-term weight maintenance while on either treatment depends on the dose, your lifestyle, and your individual response. Discuss this with your prescriber.

—

*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets (oral semaglutide) and Mounjaro (tirzepatide) are prescription-only medicines available in the UK. Always consult a registered UK healthcare professional before starting or changing treatment, and follow the patient information leaflet supplied with your medication. You must not self-switch between treatments. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk or Eli Lilly.*